key: cord-0791005-5cb8w9fd
authors: Generali, Daniele; Bosio, Giancarlo; Malberti, Fabio; Cuzzoli, Antonio; Testa, Sophie; Romanini, Laura; Fioravanti, Antonio; Morandini, Alessandro; Pianta, Luca; Giannotti, Guglielmo; Viola, Erika Maria; Pier-Franceschi, Matteo Giorgi; Foramitti, Marina; Tira, Rosa Angela; Zangrandi, Ilaria; Chiodelli, Giulia; Machiavelli, Andrea; Cappelletti, Maria Rosa; Giossi, Alessia; De Giuli, Valeria; Costanzi, Chiara; Campana, Chiara; Bernocchi, Ottavia; Sirico, Marianna; Zoncada, Alessia; Molteni, Alfredo; Venturini, Sergio; Giudici, Fabiola; Scaltriti, Maurizio; Pan, Angelo
title: Canakinumab as treatment for COVID-19-related pneumonia: a prospective case-control study
date: 2020-12-29
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.12.073
sha: 1463d312c987f976d880137d58050f3e927d33e0
doc_id: 791005
cord_uid: 5cb8w9fd

OBJECTIVES: Canakinumab is an IL-1β antibody that neutralizes the activity of IL-1β. We studied the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. DESIGN: The aim of our study was to evaluate the reduction in duration of hospitalization with adequate oxygen status. Forty-eight patients with moderate COVID-19-related pneumonia were asked to participate in the prospective case-control study; 33 patients (Cases) signed informed consent and received canakinumab (Cohort 1); 15 patients (Controls) refused to receive the experimental drug and received institutional standard of care (SoC), (Cohort 2). RESULTS: Hospital discharge within 21 days was seen in 63% of patients in Cohort 1 vs. 0% in Cohort 2 (median 14 vs 26 days, respectively; p < 0.001). There was significant clinical improvement in ventilation regimes following administration of canakinumab compared to Cohort 2 (Stuart-Maxwell test for paired data, p < 0.001). Patients treated with canakinumab experienced a significant increase in PaO(2):FiO(2) (p < 0.001) and reduction in lung damage by CT (p = 0.01), along with significant decreases in immune/inflammation markers that were not observed in Cohort 2. Only mild side effects were seen in patients treated with canakinumab; survival at 60 days was 90.0% (95% CI: 71.9-96.7) in patients treated with canakinumab and 73.3% (95% CI: 43.6-89.1) for Cohort 2. CONCLUSIONS: Treatment with canakinumab in patients with COVID-19-related pneumonia rapidly restored normal oxygen status, decreased the need for invasive mechanical ventilation, and was associated with earlier hospital discharge and favorable prognosis versus SoC.

SARS coronaviruses (SARS-CoV) are a large family of viruses that normally cause mild to moderate upper-respiratory tract illnesses (Trivedi et al., 2019) . The novel coronavirus SARS-CoV-2 is currently causing a global pandemic as declared by the World Health Organization on March 11, 2020. Sepsis, respiratory failure, acute respiratory distress syndrome (ARDS), and multi-organ failure are the common complications of an apparently aberrant host immune response (Huang et al., 2020) . Huang et al. reported the clinical features of patients infected by and suggested that hyperstimulation of cytokines, such as interferon gamma, interleukin (IL)-1, IL-6, and tumor necrosis factor α, is associated with the severity and clinical complexity of the infection (Huang et al., 2020) . Indeed, it is becoming increasingly evident that these complications are related to the so-called cytokine storm observed in some severe patients involving release of cytokines including IL-6, IL-18, and interferon (Mehta et al., 2020 , Zhang et al., 2020 . The clinical complications impede alveolar gas exchange and trigger dissemination of systemic thrombosis. Consistently, infection of cells in the lower respiratory tract by COVID-19 can give rise to severe ARDS with consequent release of additional pro-inflammatory cytokines such as IL-1β (Conti et al., 2020 , Toldo et al., 2020 .

To date, therapeutic options for severe COVID-19 remain limited. Antiviral drugs such as lopinavir/ritonavir have shown no benefits compared to standard care J o u r n a l P r e -p r o o f (Cao et al., 2020) . Recently, remdesevir was reported to have modest clinical benefits in patients affected by COVID-19 (Beigel et al., 2020) . Thus, new treatment strategies are urgently needed to achieve a significant impact on prognosis of COVID-19. The suspicion that overzealous immune responses in some COVID-19 patients have given rise to interest in anti-cytokine therapy to mitigate the cytokine-storm (Megna et al., 2020 , Zhou et al., 2020 . Accordingly, immune-modulatory agents such as anti-IL-6, anti-IL-6R, and anti-IL-1 antibodies are under investigation. Recently, the anti-IL-1R agent anakinra and tocilizumab, an anti-IL-6R, have shown promising results in patients with COVID-19 and ARDS (Campochiaro et al., 2020 , Cavalli et al., Colaneri et al., 2020 . Canakinumab is a high-affinity human monoclonal antihuman IL-1β antibody of the IgG1/κ isotype designed to block the interaction of IL-1β with its receptor, thus neutralizing its activity (Goh et al., 2014) .

Here, we investigated the clinical efficacy of canakinumab in patients with moderate COVID-19 pneumonia. The aim of our study was to evaluate the reduction in duration of hospitalization with adequate oxygen status. Secondary, we focused on survival without the need for invasive mechanical ventilation, adverse events, modulation of biological parameters, and chest computed tomography (CT) response.

The main focus was to obtain information on the activity and safety of canakinumab in patients moderate COVID-19 related-pneumonia. This prospective case-control, single-center, observational study carried out at the Azienda Socio-Sanitaria Territoriale di Cremona (ASST), Cremona (Italy) was approved by the ASST of Cremona Institutional Review Board and is without a trial registration number. All study participants gave written informed consent for participation. Studies were conducted in conformity with applicable local requirements and regulations regarding the protection of the rights and welfare of human subjects enrolled. The authors conceived the study, collected all the data, vouch for the accuracy and completeness of the data, and made the decision, after the final version, to submit the manuscript for publication. The first draft of the manuscript was conceived and prepared by the first author who is principal investigator of the study. The study drug, canakinumab, was provided by Novartis Farma, SpA.

A total of 48 patients with moderate COVID-19 related-pneumonia were enrolled in this prospective case-control study between April 1 to 25, 2020 at a single institution; 33 patients were treated with canakinumab (Cohort 1), whereas 15 patients Revolution EVO (GE Healthcare) in a whole-lung, low-dosage exposure mode, scanning with 1,25 mm slices. The software used for CT scan analysis was Thoracic VCAR, using a modified protocol with a suitable threshold to detect solid/sub-solid pulmonary changes. Lung involvement was automatically reported as a percentage by two independent radiologists. The mean of the scores was used for subsequent analysis. Safety and adverse events were monitored using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.

Canakinumab (150 mg) was administered by subcutaneous injection on day 1 and on day 7 as approved for auto-inflammatory conditions (EMA authorization Jan 30, 2020) . In 3 patients, the schedule was empirically interrupted after the first dose given the substantial clinical and radiological benefits observed.

All patients meeting eligibility criteria who had signed a consent form and who had begun experimental treatment were evaluated as a case group (Cohort 1). All eligible patients who initiated treatment were evaluated for adverse events. Patients hospitalized in the same period who refused to be treated with the experimental drug (Cohort 2) were used as a control group.

Two independent statisticians blinded to each other analyzed the data.

Continuous variables were expressed as median (range) or mean (standard deviation), according to data distribution checked with Shapiro-Wilk test. Categorical variables were expressed as absolute frequencies and percentages. Homogeneity of baseline characteristics between the two cohorts were assessed through t-test or Mann-Whitney test. One-way ANOVA or Friedman test for repeated measures were performed to evaluate differences in clinical parameters over time for both cohorts (separately). Pairwise post-hoc contrasts were considered and p values adjusted for multiple comparisons (Holm method). Type of ventilation before and after treatment was compared using the Stuart-Maxwell test. Spearman's linear coefficient was calculated to assess correlation between variables of interest. Linear mixed-effect models (LMEM) for repeated measures were used to investigate changes in values over time with respect to group assignment. The method used to treat missing data was complete data analysis: the percentage of missing values across variables of interest over time varied between 0% and 27% for cohort 1 (at maximum 9 missing values for variables) and between 0% and 13% for patients in cohort 2 (at maximum 2 missing values for variables). Missing values can be considered as completely random due to the emergency situation. Overall survival (OS) was defined as the time from date of admission to hospital to death and estimated with Kaplan-Meier method.

Last follow-up update was on May 27, 2020. Log-rank test was conducted to assess J o u r n a l P r e -p r o o f differences between groups. All statistical analyses were performed using R version 4.0.0. Statistical significance was set as p <0.05.

From April 1 st to April 25 th , 2020, 48 patients with moderate COVID-19 and pneumonia were included; 33 were treated with canakinumab (Cohort 1), whereas 15 (Cohort 2) received the institutional standard of care. All patients were managed outside of the ICU. Baseline characteristics are summarized in Table 1 . Median age was similar in cohort 1 (70 years, range 29-89) and Cohort 2 (69 years, range 44-85).

The majority of patients were male (76% for Cohort 1 and 87% in Cohort 2). The range of comorbidities and presenting symptoms were broadly similar in both groups.

Patients in both groups had received treatment with antivirals, hydroxychloroquine, and antibiotics (see Supplementary Appendix) before entering the study. In Cohort 1, for treatment of COVID-19 related pneumonia, patients received canakinumab and heparin; Cohort 2 received high dose (10,000 IU) heparin only. We also compared the PaO2:FiO2 ratio and chest CT before starting canakinumab and at 7 to 10 days after the second injection of the anti-IL1β antibody.

We performed the same comparison in Cohort 2 during the same time frame of patients receiving canakinumab. The ventilation approaches in the two cohorts were comparable at baseline; however, after administration of canakinumab more patients needed less invasive types of ventilation. As shown in Table 2 , compared to baseline, patients treated with canakinumab experienced a significant increase of the PaO2:FiO2 ratio (p<0.001) and a reduction in lung damage evaluated by CT (p=0.01). Cohort 2 had clinical benefit only in the PaO2:FiO2 ratio (p=0.05). We did not observe any J o u r n a l P r e -p r o o f significant correlation between the change (Δ) in PaO2:FiO2 ratio, or Δ in lung damage in controls (Table S1 ). Figure 1 shows the changes in lung damage related to COVID-19 induced by canakinumab.

Laboratory immune and inflammatory markers were tested prior to administration of canakinumab at days 1 and 7 and at 7-10 days after the second injection of the antibody (Table S2 ). Canakinumab led to a reduction in white blood cells (p<0.001), platelets (p=0.005) and neutrophils (p <0.001), and an increase in lymphocytes (p=0.01), over the time of measurement, while no significant variations were found for the same parameters in Cohort 2 (Fig. 2a) . The changes over time in immune and inflammatory markers are reported in Tables S3a and S3b, and in Tables   S4a and S4b , respectively. Moreover, the neutrophil/lymphocyte ratio, considered as a surrogate marker of response to treatment in other settings such as cancer (Kim et al., 2019) , showed a significant increase (p<0.001) over time. This trend was not observed in cohort 2 where only an increase in neutrophil count was seen pretreatment and before the 2nd administration (p=0.05).

With regards to inflammatory markers, canakinumab treatment was associated with prompt reductions in serum CRP (p<0.001), IL-6 (p<0.03), and ferritin (p<0.001).

In Cohort 2, only a reduction in the level of D-dimer was noted (p=0.05) (Fig. 2b) , which was likely due to the higher dose of heparin used compared to cohort 1.

Effects of time, irrespective of treatment, were found in WBC, neutrophils, and at the limit of statistical significance in CRP. Interactions between time and treatment were significant for WBC, lymphocytes, neutrophils, platelets, CRP, and the neutrophils/lymphocyte ratio (Table S5 and Fig. 2a) .

Clinical outcomes of the 33 patients treated with canakinumab were compared to those of the 15 patients who received standard treatment only. We observed an improvement in survival in cohort 1. The survival rate at 60 days was 90.0% (95% CI: 71.9-96.7) in the canakinumab-treated cohort vs. 73.3% (95% CI: 43.6-89.1) in cohort 2 (Fig. 3a) . Moreover, in Cohort 1 (canakinumab-treated cohort), 63% of patients were hospitalized for less than 21 days compared to 0% in Cohort 2 (median 14 vs 26 days, respectively; p<0.001) ( Table 1) In both cohorts, heparin, independently of the dose, was well tolerated without any serious adverse events. In the group treated with canakinumab, 4 patients experienced injection site reactions, while 2 experienced nausea (Grade 1), and 1 patient referred headache (Grade 1). These symptoms were not recorded in patients in the standard of care group.

In the absence of standard of care, existing therapies can potentially be repurposed to treat COVID-19. This pandemic has favored the off-label or compassionate use of investigational agents such as remdesivir, immune-modulating compounds, or convalescent plasma (Lima et al., 2020 , Manhas et al., 2020 that are approved or licensed for other indications. To date, the use of other immunomodulatory agents such as tocilizumab and anakinra for the treatment of the cytokine storm related to COVID-19 has highlighted the potential importance of modulating this pathway in preventing worsening of disease (Campochiaro et al., 2020 , Cavalli et al., Colaneri et al., 2020 . It has also been reported that tocilizumab reduced admissions to the ICU and mortality in patients with COVID-19 (Klopfenstein et al., 2020) .

A recent retrospective analysis of 10 patients with COVID-19-prenumonia who were treated safely with canakinumab (Ucciferri et al., 2020) showed that all patients recovered within 45 days along an improvement of oxygenation and a decrease in the systemic inflammatory response. The PaO2:FiO2 ratio increased in 82% of patients, while improvement of oxygen-support category was observed in 61% of cases. Overall, mortality was 13.6%.

Herein, we report, in a real-world setting, the activity of canakinumab for the treatment of patients with moderate COVID-19-pneumonia. The recent data about the J o u r n a l P r e -p r o o f intense inflammasome formation characterizing the lungs of patients with fatal COVID-19 disease due to acute respiratory distress syndrome (ARDS) support a rational role of canakinumab in managing COVID-19-related complications (Conti et al., 2020 , Toldo et al., 2020 ). Moreover, we found that, in most patients (heavily pretreated with antivirals and hydroxychloroquine), hypoxemia, and lung CT opacity both improve rapidly after treatment with canakinumab, compared to Cohort 2, suggesting that IL-1β blockade could play an important role in modulating the cytokine storm. Of note, canakinumab was also associated with significant time to clinical improvement vs Cohort 2.

An increase in the percentage of lymphocytes with a concomitant increase in neutrophils is considered to be an important indicator for immune response in clinical settings (Zahorec, 2001) . Levels of both CRP and IL-6 decreased during therapy with canakinumab (p=0.02; Figure S1 ), along with a slight reduction in markers related to complements C3 and C4 (data not shown), supporting the role of canakinumab in modulating the immune response/cytokine storm. It is likely that canakinumab is more efficacious before the patient's condition progresses from mild to severe (e.g. increase of lung opacity, increased IL-6, CRP, and hypoxemia), as early treatment may effectively control the deterioration of symptoms and complications related to the massive cytokine storm observed in patients with severe forms of COVID-19.

However, the long-term safety of IL-1 inhibition remains to be investigated.

Specifically, canakinumab produces sustained IL-1 suppression and therefore vigilance is necessary to monitor for adverse events.

All our patients were treated with hydroxychloroquine, lopinavir/ritonavir or remdesivir, alone or in combination, before starting canakinumab. The variety of treatment schedules used was related to the absence of defined treatment protocols during the first few weeks of the COVID-19 epidemic. In our analysis, we evaluated the potential therapeutic efficacy of canakinumab/heparin versus heparin alone without the interference of other drugs, which were suspended before starting the study accordingly to SIMIT guidelines .

Even considering the emergency situation when the study was performed, there are several limitations in our work. The number of patients is relatively limited, as in many similar studies with preliminary but encouraging findings. The uncontrolled nature of our study mandates caution in interpretation of the results; it was a prospective, non-randomized study and some bias is possible. However, based on these results, a randomized, controlled trial with canakinumab in COVID-19pneumonia is warranted in outpatients with manageable disease. A randomized phase III clinical trial with intravenous canakinumab in hospitalized patients with COVID-19induced pneumonia is on-going (NCT04362813), but this study will assess the efficacy of a higher dose (administered IV and by body weight). 

Summary of Product Characteristics

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)

Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies

A novel human anti-interleukin-1beta neutralizing monoclonal antibody showing in vivo efficacy

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

The Role of Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio in Predicting Neoadjuvant Chemotherapy Response in Breast Cancer

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review

Lombardy Section Italian Society I, Tropical D. Vademecum for the treatment of people with COVID-19

Pandemic and Current Medical Interventions

May IL-17 have a role in COVID-19 infection?

COVID-19: consider cytokine storm syndromes and immunosuppression

Inflammasome formation in the lungs of patients with fatal COVID-19

Development and Evaluation of a Multiplexed Immunoassay for Simultaneous Detection of Serum IgG Antibodies to Six Human Coronaviruses

Canakinumab in a subgroup of patients with COVID-19

Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill

Clinical characteristics of 82 cases of death from COVID-19